Antiphospholipid syndrome

Thrombosis Research

Volumn 151, Issue , 2017, Pages S43-S47

  Cervera, Ricard ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Anticardiolipin antibodies; Antiphospholipid syndrome; Catastrophic antiphospholipid syndrome; Lupus anticoagulant

Indexed keywords

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; DISEASE CLASSIFICATION; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; COMPLICATION; FEMALE; IMMUNOLOGY; PREGNANCY; PREGNANCY COMPLICATIONS; THROMBOSIS;

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; HEPARIN; PHOSPHOLIPID ANTIBODY;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; THROMBOSIS;

EID: 85014363742     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(17)30066-X     Document Type: Article

References (30)

1. [1] Cervera, R., Espinosa, Khamashta, M.A., Antiphospholipid syndrome in systemic autoimmune diseases, 2nd edition, 2016, Elsevier, Amsterdam.
2. [2] Cervera, R., Asherson, R.A., Acevedo, M.L., Gomez-Puerta, J.A., Espinosa, G., De La Red, G., et al. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis 63 (2004), 1312–1317.
3. [3] Gómez-Puerta, J.A., Cervera, R., Espinosa, G., Aguiló, S., Bucciarelli, S., Ramos-Casals, M., et al. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum 35 (2006), 322–332.
4. [4] Gómez-Puerta, J.A., Martin, H., Amigo, M.C., Aguirre, M.A., Camps, M.T., Cuadrado, M.J., et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?. Medicine (Baltimore) 84 (2005), 225–230.
5. [5] Rodriguez-Pintó, I., Moitinho, M., Santacreu, I., Shoenfeld, Y., Erkan, D., Espinosa, G., et al. Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev 15 (2016), 1120–1124.
6. [6] Durcan, L., Petri, M., Epidemiology of the Antiphospholipid Syndrome. Cervera, R., Espinosa, Khamashta, M.A., (eds.), 2nd edition Antiphospholipid syndrome in systemic autoimmune diseases, 2016, Elsevier, Amsterdam, 17–30.
7. [7] Andreoli, L., Chighizola, C.B., Banzato, A., Pons-Estel, G.J., Ramire de Jesus, G., Erkan, D., Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken) 65 (2013), 1869–1873.
8. [8] Cervera, R., Espinosa, G., Bucciarelli, S., Gomez-Puerta, J.A., Font, J., Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry. Autoimmun Rev 6 (2006), 81–84.
9. [9] Cervera, R., Bucciarelli, S., Plasin, M.A., Gomez-Puerta, J.A., Plaza, J., Pons-Estel, G., et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry”. J Autoimmun 32 (2009), 240–245.
10. [10] Espinosa, G., Cervera, R., Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. Nat Rev Rheumatol 6 (2010), 296–300.
11. [11] Giannakopoulos, B., Krilis, S.A., The pathogenesis of the antiphospholipid syndrome. N EnglJ Med 368 (2013), 1033–1044.
12. [12] Cervera, R., Piette, J.C., Font, J., Khamashta, M.A., Shoenfeld, Y., Camps, M.T., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46 (2002), 1019–1027.
13. [13] Cervera, R., Khamashta, M.A., Shoenfeld, Y., Camps, M.T., Jacobsen, S., Kiss, E., et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 68 (2009), 1428–1432.
14. [14] Cervera, R., Serrano, R., Pons-Estel, G.J., Ceberio-Hualde, L., Shoenfeld, Y., de Ramón, E., et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 74 (2015), 1011–1018.
15. [15] Ruffatti, A., Calligaro, A., Hoxha, A., Trevisanuto, D., Ruffatti, A.T., Gervasi, M.T., et al. Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res (Hoboken) 62 (2010), 302–307.
16. [16] Sciascia, S., Sanna, G., Murru, V., Roccatello, D., Khamashta, M.A., Bertolaccini, M.L., GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford) 52 (2013), 1397–1403.
17. [17] Wilson, W.A., Gharavi, A.E., Koike, T., Lockshin, M.D., Branch, D.W., Piette, J.C., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42 (1999), 1309–1311.
18. [18] Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006), 295–306.
19. [19] Kaul, M., Erkan, D., Sammaritano, L., Lockshin, M.D., Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis 66 (2007), 927–930.
20. [20] Asherson, R.A., Cervera, R., de Groot, P.G., Erkan, D., Boffa, M.C., Piette, J.C., et al. Catastrophic antiphospholipid syndrome: International consensus statement on classification criteria and treatment guidelines. Lupus 12 (2003), 530–534.
21. [21] Cervera, R., Font, J., Gomez-Puerta, J.A., Espinosa, G., Cucho, M., Bucciarelli, S., et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 64 (2005), 1205–1209.
22. [22] Ruiz-Irastorza, G., Cuadrado, M.J., Ruiz-Arruza, I., Brey, R., Crowther, M., Derksen, R., et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 20 (2011), 206–218.
23. [23] Andrade, D., Cervera, R., Cohen, H., Crowther, M., Cuadrado, M., Canaud, G., et al. Erkan, D., Lockshin, M., (eds.), 15th International Congress on Antiphospholipid Antibodies - Task Force on Antiphospholipid Syndrome Treatment Trends Report, 2017, APS Current Research Highlights and Clinical Insights, Springer (in press).
24. [24] Erkan, D., Vega, J., Ramon, G., Kozora, E., Lockshin, M.D., A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum 65 (2013), 464–771.
25. [25] Berman, H., Rodriguez-Pinto, I., Cervera, R., Morel, N., Costedoat-Chalumeau, N., Erkan, D., et al. Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 12 (2013), 1085–1090.
26. [26] Shapira, I., Andrade, D., Allen, S.L., Salmon, J.E., Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 64 (2012), 2719–2723.
27. [27] Erkan, D., Harrison, M.J., Levy, R., Peterson, M., Petri, M., Sammaritano, L., et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphos-pholipid antibody-positive individuals. Arthritis Rheum 56 (2007), 2382–2391.
28. [28] Espinosa, G., Cervera, R., Current treatment of antiphospholipid syndrome: lights and shadows. Nat Rev Rheumatol 11 (2015), 586–596.
29. [29] Gómez-Puerta, J.A., Cervera, R., Are there additional options for the treatment of refractory obstetric antiphospholipid syndrome?. Lupus 22 (2013), 754–755.
30. [30] Grika, E.P., Ziakas, P.D., Zintzaras, E., Moutsopoulos, H.M., Vlachoyiannopoulos, P.G., Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol 39 (2012), 516–523.